beta-chimaerin

MW 30 kDa; GTPase-activating protein for p21rac which is highly related to n-chimaerin; specifically expressed during the acrosomal assembly stage in rat testis; associated with malignant transformation in astrocytoma; amino acid sequence given in first source

Also Known As:

Networked: 7 relevant articles (0 outcomes, 1 trials/studies)

Bio-Agent Context: Research Results

Experts

1.	Kazanietz, Marcelo G: 3 articles (09/2009 - 05/2003)
2.	Alonso, Daniel F: 2 articles (01/2005 - 05/2003)
3.	Gomez, Daniel E: 2 articles (01/2005 - 05/2003)
4.	Menna, Pablo Lorenzano: 2 articles (01/2005 - 05/2003)
5.	Blumberg, Peter M: 1 article (09/2009)
6.	Choi, Sung-Hee: 1 article (09/2009)
7.	Lewin, Nancy E: 1 article (09/2009)
8.	Sosa, Maria Soledad: 1 article (09/2009)
9.	Baranski, Thomas J: 1 article (10/2007)
10.	Bruinsma, Stephen P: 1 article (10/2007)

Related Diseases

1.	Neoplasms (Cancer) 09/01/2009 - "Recent studies established that the Rac-GAP beta2-chimaerin plays important roles in development, neuritogenesis, and cancer progression. " 10/15/2007 - "Emerging evidence implicates beta2-chimaerin in tumor progression. " 09/01/2007 - "beta2-Chimaerin negatively controls many Rac-dependent pathophysiological events including tumor development. " 05/01/2003 - "Our results indicate that beta2-chimaerin impairs key steps in the metastatic cascade and provide evidence for a rational modulation of the Rac signaling pathway in cancer treatment." 10/15/2007 - "Beta2-chimaerin in cancer signaling: connecting cell adhesion and MAP kinase activation."
2.	Carcinoma (Carcinomatosis) 01/01/2005 - "Role of beta2-chimaerin in the behaviour of murine mammary carcinoma cells in response to extracellular matrix components." 05/01/2003 - "Inhibition of aggressiveness of metastatic mouse mammary carcinoma cells by the beta2-chimaerin GAP domain." 05/01/2003 - "To explore the potential role of beta2-chimaerin in invasion and metastasis, we generated stable transfectants for its catalytic domain (the beta-GAP domain) in F3II murine mammary carcinoma cells. " 01/01/2005 - "In this work, we analysed cell morphology, actin cytoskeleton reorganisation and metalloprotease (MMP) secretion in response to matrix proteins in mouse mammary carcinoma cells transfected with the beta2-chimaerin GAP domain. "
3.	Atherosclerosis 04/01/2006 - "The signaling mediated by beta2-chimaerin may play a role in the regulation of SMC phenotypes, thereby implicating human atherogenesis."
4.	Neoplasm Metastasis (Metastasis) 05/01/2003 - "To explore the potential role of beta2-chimaerin in invasion and metastasis, we generated stable transfectants for its catalytic domain (the beta-GAP domain) in F3II murine mammary carcinoma cells. "
5.	Glioma (Gliomas) 08/01/1995 - "The down-regulation of beta 2-chimaerin expression in the high-grade gliomas suggests that decreased expression of this gene may be a feature of progression in the development of malignant glioma."

Related Drugs and Biologics

1.	Metalloproteases (Metalloproteinases)
2.	Matrix Metalloproteinases (MMPs)
3.	Proteins (Proteins, Gene)
4.	Phosphotransferases (Kinase)